NCT03234751

Effect of Nesiritide Infusion on Insulin Sensitivity in Healthy Obese Insulin Resistant Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 6 (actual)
• Sponsor: AdventHealth Translational Research Institute · Academic / Other
• Sex: All
• Age: 40 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The purpose of the study is to compare the effects of nesiritide to placebo administered by a continuous IV infusion over 48 hours for the treatment of insulin resistance in healthy, obese, insulin resistant individuals.

Conditions

• Diabetes

Interventions

Type	Name	Description
DRUG	Continous IV infusion of Nesiritide	Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.
DRUG	Hyperinsulinemic euglycemic clamp	48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.
DRUG	Placebo	48 hours of placebo.

Timeline

• Start date: 2017-07-13
• Primary completion: 2018-09-24
• Completion: 2020-02-19
• First posted: 2017-07-31
• Last updated: 2020-03-10

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study